Gynecologic Cancer News

CHICAGO — Individuals with advanced cancer who received a two-component medical cannabis oil reported improvement in cancer-related pain, results from a randomized study showed.

Individuals with therapy-refractory cancer who received waivers to participate in a clinical trial for off-label targeted therapies achieved similar clinical benefits as those who took part in the study without an exception.

Robert A. Winn, MD, FAACR, first called for celebration.

The FDA approved the use of durvalumab in combination with carboplatin and paclitaxel followed by single-agent durvalumab for women with mismatch repair-deficient primary advanced or recurrent endometrial cancer.

Past-year Pap smear testing rates were lower in 2022 than in 2019, highlighting the need to increase screening access, especially in rural areas, to prevent cervical cancer, researchers reported in JAMA Network Open.

The FDA approved the use of pembrolizumab in combination with chemotherapy for adults with primary advanced or recurrent endometrial carcinoma.

An analysis of the online conversations of more than 1,000 health care professionals worldwide through May revealed positive reactions to the approval of three key treatment options for patients with cancer.

BOSTON — People with primary ovarian insufficiency have higher risk for breast cancer and borderline increased risk for ovarian cancer compared with the general population, and risks for some cancers extend to their relatives, data show.

Endometriosis was significantly associated with higher risks for both ovarian and endometrial cancers, but was not significantly associated with cervical cancer risk, according to an analysis published in Current Oncology.

A trial investigating mirvetuximab soravtansine monotherapy in certain patients with platinum-sensitive ovarian cancer met its primary endpoint of improved objective response rate, according to the agent’s manufacturer.